Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009

Alfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes

Research output: Contribution to journalReview article

Abstract

Homoharringtonine (HHT) is a natural alkaloid that is obtained from various Cephalotaxus species. The mechanism of action by which HHT exerts its antitumor activity is through inhibition of protein synthesis and promotion of apoptosis. In the 1990s, HHT proved to be significantly active as salvage therapy for patients with chronic myeloid leukemia (CML) after failure on interferon-α therapy. However, the remarkable success of imatinib mesylate in the treatment of CML relegated HHT to oblivion. The development of omacetaxine mepesuccinate, a subcutaneously bioavailable semisynthetic form of HHT, and its activity in imatinib-resistant CML has established this agent for the second time as a valuable option in the management of this disease. Preliminary results appear to support the use of this agent for patients who have imatinib-resistant CML, including those who carry the tyrosine kinase inhibitor-insensitive mutation that exchanges the amino acids threonine and isoleucine at position 315 (the T315I mutation). In this article, the authors discuss the current data on omacetaxine and the prospects of this agent to be integrated into the state-of-the-art treatment algorithms for CML.

Original languageEnglish (US)
Pages (from-to)5382-5393
Number of pages12
JournalCancer
Volume115
Issue number23
DOIs
StatePublished - Jan 12 2009
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cephalotaxus
Salvage Therapy
Mutation
Isoleucine
Proxy
Threonine
Disease Management
Alkaloids
Protein-Tyrosine Kinases
Interferons
homoharringtonine
Therapeutics
Apoptosis
Amino Acids
Imatinib Mesylate
Proteins

Keywords

  • BCR-ABL1 mutations
  • Chronic myeloid leukemia
  • Homoharringtonine
  • Omacetaxine mepesuccinate
  • T315I

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. / Quintás-Cardama, Alfonso; Kantarjian, Hagop; Cortes, Jorge.

In: Cancer, Vol. 115, No. 23, 12.01.2009, p. 5382-5393.

Research output: Contribution to journalReview article

Quintás-Cardama, Alfonso ; Kantarjian, Hagop ; Cortes, Jorge. / Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. In: Cancer. 2009 ; Vol. 115, No. 23. pp. 5382-5393.
@article{a89ea4fa5f1c46feb1103d34410d6e08,
title = "Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009",
abstract = "Homoharringtonine (HHT) is a natural alkaloid that is obtained from various Cephalotaxus species. The mechanism of action by which HHT exerts its antitumor activity is through inhibition of protein synthesis and promotion of apoptosis. In the 1990s, HHT proved to be significantly active as salvage therapy for patients with chronic myeloid leukemia (CML) after failure on interferon-α therapy. However, the remarkable success of imatinib mesylate in the treatment of CML relegated HHT to oblivion. The development of omacetaxine mepesuccinate, a subcutaneously bioavailable semisynthetic form of HHT, and its activity in imatinib-resistant CML has established this agent for the second time as a valuable option in the management of this disease. Preliminary results appear to support the use of this agent for patients who have imatinib-resistant CML, including those who carry the tyrosine kinase inhibitor-insensitive mutation that exchanges the amino acids threonine and isoleucine at position 315 (the T315I mutation). In this article, the authors discuss the current data on omacetaxine and the prospects of this agent to be integrated into the state-of-the-art treatment algorithms for CML.",
keywords = "BCR-ABL1 mutations, Chronic myeloid leukemia, Homoharringtonine, Omacetaxine mepesuccinate, T315I",
author = "Alfonso Quint{\'a}s-Cardama and Hagop Kantarjian and Jorge Cortes",
year = "2009",
month = "1",
day = "12",
doi = "10.1002/cncr.24601",
language = "English (US)",
volume = "115",
pages = "5382--5393",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "23",

}

TY - JOUR

T1 - Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009

AU - Quintás-Cardama, Alfonso

AU - Kantarjian, Hagop

AU - Cortes, Jorge

PY - 2009/1/12

Y1 - 2009/1/12

N2 - Homoharringtonine (HHT) is a natural alkaloid that is obtained from various Cephalotaxus species. The mechanism of action by which HHT exerts its antitumor activity is through inhibition of protein synthesis and promotion of apoptosis. In the 1990s, HHT proved to be significantly active as salvage therapy for patients with chronic myeloid leukemia (CML) after failure on interferon-α therapy. However, the remarkable success of imatinib mesylate in the treatment of CML relegated HHT to oblivion. The development of omacetaxine mepesuccinate, a subcutaneously bioavailable semisynthetic form of HHT, and its activity in imatinib-resistant CML has established this agent for the second time as a valuable option in the management of this disease. Preliminary results appear to support the use of this agent for patients who have imatinib-resistant CML, including those who carry the tyrosine kinase inhibitor-insensitive mutation that exchanges the amino acids threonine and isoleucine at position 315 (the T315I mutation). In this article, the authors discuss the current data on omacetaxine and the prospects of this agent to be integrated into the state-of-the-art treatment algorithms for CML.

AB - Homoharringtonine (HHT) is a natural alkaloid that is obtained from various Cephalotaxus species. The mechanism of action by which HHT exerts its antitumor activity is through inhibition of protein synthesis and promotion of apoptosis. In the 1990s, HHT proved to be significantly active as salvage therapy for patients with chronic myeloid leukemia (CML) after failure on interferon-α therapy. However, the remarkable success of imatinib mesylate in the treatment of CML relegated HHT to oblivion. The development of omacetaxine mepesuccinate, a subcutaneously bioavailable semisynthetic form of HHT, and its activity in imatinib-resistant CML has established this agent for the second time as a valuable option in the management of this disease. Preliminary results appear to support the use of this agent for patients who have imatinib-resistant CML, including those who carry the tyrosine kinase inhibitor-insensitive mutation that exchanges the amino acids threonine and isoleucine at position 315 (the T315I mutation). In this article, the authors discuss the current data on omacetaxine and the prospects of this agent to be integrated into the state-of-the-art treatment algorithms for CML.

KW - BCR-ABL1 mutations

KW - Chronic myeloid leukemia

KW - Homoharringtonine

KW - Omacetaxine mepesuccinate

KW - T315I

UR - http://www.scopus.com/inward/record.url?scp=72249090201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72249090201&partnerID=8YFLogxK

U2 - 10.1002/cncr.24601

DO - 10.1002/cncr.24601

M3 - Review article

C2 - 19739234

AN - SCOPUS:72249090201

VL - 115

SP - 5382

EP - 5393

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 23

ER -